Attached files
| file | filename |
|---|---|
| EX-21.1 - EXHIBIT 21.1 - NORTHWEST BIOTHERAPEUTICS INC | tm205288d1_ex21-1.htm |
| EX-31.2 - EXHIBIT 31.2 - NORTHWEST BIOTHERAPEUTICS INC | tm205288d1_ex31-2.htm |
| EX-32.1 - EXHIBIT 32.1 - NORTHWEST BIOTHERAPEUTICS INC | tm205288d1_ex32-1.htm |
| EX-32.2 - EXHIBIT 32.2 - NORTHWEST BIOTHERAPEUTICS INC | tm205288d1_ex32-2.htm |
| EX-31.1 - EXHIBIT 31.1 - NORTHWEST BIOTHERAPEUTICS INC | tm205288d1_ex31-1.htm |
| EX-4.1 - EXHIBIT 4.1 - NORTHWEST BIOTHERAPEUTICS INC | tm205288d1_ex4-1.htm |
| 10-K - FORM 10-K - NORTHWEST BIOTHERAPEUTICS INC | tm205288-1_10k.htm |
Exhibit 23.1
Independent Registered Public Accounting Firm’s Consent
We consent to the incorporation by reference in the Registration Statement of Northwest Biotherapeutics, Inc. on Form S-3 [File No. 333-213777 and 333-234248] of our report dated March 16, 2020, which includes an explanatory paragraph as to the Company’s ability to continue as a going concern, with respect to our audits of the consolidated financial statements of Northwest Biotherapeutics, Inc. as of December 31, 2019 and 2018 and for the years ended December 31, 2019 and 2018 and our report dated March 16, 2020, with respect to our audit of the effectiveness of internal control over financial reporting of Northwest Biotherapeutics, Inc. as of December 31, 2019, which reports are included in this Annual Report on Form 10-K of Northwest Biotherapeutics, Inc. for the year ended December 31, 2019.
Our report on the consolidated financial statements refers to a change in the method of accounting for leases due to the adoption of the guidance in ASC Topic 842 effective January 1, 2019.
/s/ Marcum LLP
Marcum LLP
New York, NY
March 16, 2020